Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Biogen faces revenue challenges as Leqembi sales lag projections. Investors watch its pipeline expansion and strategic moves amid upcoming Q4 earnings.

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Research supporting the amyloid hypothesis—the idea that Alzheimer's is caused by a buildup of amyloid plaques in the ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

The Scottish Medicines Consortium announced lecanemab would not be made available on the NHS, following a similar decision ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.

Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived ...